Contineum Therapeutics, Inc. - 10-Q Filing

Contineum Therapeutics reports third quarter 2026 financial results including details on At-The-Market offering activity and equity incentive plans.

SEC EDGAR ·

Tickers: $CTNM

Read the full article at SEC EDGAR

More Regulatory news